Literature DB >> 31318511

What are the potential savings from steering patients to lower-priced providers? a static analysis.

Sunita M Desai1, Laura A Hatfield, Andrew L Hicks, Michael E Chernew, Ateev Mehrotra, Anna D Sinaiko.   

Abstract

OBJECTIVES: Healthcare payers are increasingly using price transparency and benefit design to encourage patients to choose lower-priced providers. We quantify potential savings from shifting patients to lower-priced providers. If there is limited price variation or if higher-priced providers command little market share, savings could be minimal. STUDY
DESIGN: Using 2013-2014 commercial claims for 697,381 enrollees in California, we characterized within-market price variation and the relationship between providers' market shares and relative prices for 3 nonemergent, shoppable outpatient services: laboratory tests, imaging services, and durable medical equipment (DME). In a stylized policy simulation that holds provider price and utilization constant, we computed potential savings if patients who visited providers with prices above the median price shifted to the median-priced provider in their geographic market for the same service.
METHODS: Observational analyses.
RESULTS: Of the service categories examined, laboratory tests had greatest within-market price variation (median coefficient of variation of 100% vs 87% for imaging services and 43% for DME). Roughly half of services (53%, 47%, and 54% for laboratory tests, imaging services, and DME, respectively) were billed by providers with prices above their market median. Shifting these patients to the median-priced provider in their markets could save 42%, 45%, and 15% of spending on laboratory tests, imaging services, and DME, respectively, together representing savings of 11% of total outpatient spending and 7% of the sum of inpatient and outpatient spending.
CONCLUSIONS: Steering patients from higher- to lower-priced providers within geographic markets in targeted service categories could generate substantial healthcare savings.

Entities:  

Mesh:

Year:  2019        PMID: 31318511

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  3 in total

1.  Costs by Site of Service for Commercially-Insured Patients with Metastatic Pancreatic Cancer Receiving Guideline-Recommended Chemotherapy: Comparing Community Oncology and Hospital Outpatient Settings.

Authors:  Samantha Tomicki; Gabriela Dieguez; David DeStephano; Melody Chang; Paul Cockrum
Journal:  Clinicoecon Outcomes Res       Date:  2022-10-10

2.  Patterns of Use of a Price Transparency Tool for Childbirth Among Pregnant Individuals With Commercial Insurance.

Authors:  Rebecca A Gourevitch; Alyna T Chien; Elizabeth A Bambury; Neel T Shah; Christine Riedl; Meredith B Rosenthal; Anna D Sinaiko
Journal:  JAMA Netw Open       Date:  2021-08-02

3.  Site-based payment differentials for ambulatory services among individuals with commercial insurance.

Authors:  Aditi P Sen; Yashaswini Singh; Gerard F Anderson
Journal:  Health Serv Res       Date:  2022-02-15       Impact factor: 3.734

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.